SEARCH

SEARCH BY CITATION

References

  • 1
    Morvay K, Szentleleki K, Torok G, Pinter A, Borzsonyi M, Nawroth R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydralazine-induced colon cancer in rats. Dis Colon Rectum 1989; 32:860863.
  • 2
    Cohen BI, Raicht RF, Deschner EE, Takahashi M, Sarwal AN, Fazzini E. Effect of cholic acid feeding on N-methyl-N-nitrosurea-induced colon tumors and cell kinetics in rats. J Natl Cancer Inst 1980; 64:573578.
  • 3
    Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995; 36:268273.
  • 4
    Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104:145151.
  • 5
    Moorehead RJ, Campbell GR, Donaldson JD, McKelvey ST. Relationship between duodenal bile acids and colorectal neoplasia. Gut 1987; 28:14541459.
  • 6
    Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977; 39:25332539.
  • 7
    Ochsenkuhn T, Bayerdorffer E, Meining A, Schinkel M, Thiede C, Nussler V, Sackman M, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85:16641669.
  • 8
    Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmac Ther 1995; 66:115.
  • 9
    Marteau Ph, Chazouilleres O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12:12061208.
  • 10
    Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995; 109:18351844.
  • 11
    Kurtz WJ, Guldutuna S, Leuschner U. Differing effect of chenodeoxycholic acid on bile acids in rat colonic wall and contents. Tokai J Exp Clin Med 1988; 13:9197.
  • 12
    Brasitus TA. Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology 1995; 109:20362039.
  • 13
    Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharryya AK, Roy H, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994; 54:50715074.
  • 14
    Poupon RE, Poupon R, Balkau B and UDCA-PBC Study Group. Ursodiol for the long term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330:13421347.
  • 15
    Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17:489503.
  • 16
    Jaskiewicz K, Lancaster E, Banach L, Karmolinski A. Proliferative activity of normal and neoplastic colonic mucosa in population groups with high and low risk for colorectal carcinoma. Anticancer Res 1998; 18:46414644.
  • 17
    Wong NA, Mayer NJ, MacKell S, Gilmour HM, Harrison DJ. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology 2000; 37:108114.
  • 18
    Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, Waye JD, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993; 328:901906.
  • 19
    Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, et al. Lack of effect of low-fat, high fiber diet on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:11491155.
  • 20
    Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 1999; 29:13961398.
  • 21
    Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R. Hepatic and extra hepatic malignancies in primary biliary cirrhosis. Hepatology 1999; 29:14251428.
  • 22
    Williams AR, Balasooriya BAW, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982; 23:835842.
  • 23
    Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca J. Adenomatous lesions of the large bowel. Cancer 1979; 43:18471857.
  • 24
    Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Int med 2001; 134:8995.
  • 25
    Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998; 58:16841687.
  • 26
    Shekels LL, Beste JE, Ho SB. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J Lab Clin Med 1996; 127:5766.
  • 27
    Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effects of bile acid and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994; 83:319323.
  • 28
    Wali RK, Frawley BP Jr., Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, Earnest DL, et al. Mechanism of action of chemopreventive ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res 1995; 55:52575267.
  • 29
    Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, et al. Ursodeoxycholic acid and f(6)-d(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin d1 and e-cadherin. Cancer Epidemiol Biomarkers Prev 2002; 11:16531662.
  • 30
    Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998; 134:129139.
  • 31
    Khare S, Wali R, Cerda S, Hart J, Sitrin M, Brasitus T, Bissonnette M. Ursodeoxycholic acid and an analogue of vitamin D inhibit COX-2 expression in AOM-induced colonic tumors and in HCA-7 cells: roles of C/EBP and VEGF [abstract]. Gastroenterology 2001; 120:A170.